Top 20 Pharmaceutical Companies by Revenue & Market Cap in 2026: GLP-1, Oncology, and Blockbuster Drugs Driving Growth
Quick answer: Based on full-year 2025 results reported between January and March 2026, Johnson & Johnson ($94.2 billion) is the world's largest pharmaceutical/healthcare company by revenue, followed by China's Sinopharm Group (~$80 billion, primarily a distributor), Roche (~$70 billion), Eli Lilly ($65.2 billion, +45%), Merck & Co. ($65.0 billion), Pfizer ($62.6 billion), AbbVie ($61.2 billion), AstraZeneca ($58.7 billion), Novartis ($54.5 billion) and Bristol Myers Squibb ($48.2 billion) rounding out the top 10. By market capitalization, Eli Lilly is far ahead of every rival at roughly $1.1 trillion, more than double Johnson & Johnson's ~$600 billion.
Table of Contents
- 2026 Top 20 Pharma Revenue & Market Cap Leaderboard (Table)
- Company-by-Company Breakdown
- Key 2026 Growth Drivers: GLP-1, Oncology & Immunology
- Frequently Asked Questions
- Methodology
.png)
The 20 largest pharmaceutical companies in the world generated a combined $950 billion-plus in revenue in 2025, spanning U.S. big pharma, European multinationals, Japanese majors, and China's largest healthcare distributor, Sinopharm Group. This expanded ranking uses each company's audited or company-reported full-year 2025 results, disclosed between January and March 2026 (Japanese firms report on a fiscal year ending March 31, so their figures reflect the closest comparable 12-month period).
2026 Top 20 Pharma Revenue & Market Cap Leaderboard
| Rank | Company | Ticker | HQ / Country | FY2025 Revenue | YoY Growth | Market Cap (Jul 2026) |
|---|---|---|---|---|---|---|
| 1 | Johnson & Johnson | NYSE: JNJ | USA | $94.2B | +6.0% | ~$600B |
| 2 | Sinopharm Group* | HKEX: 1099 | China | ~$80.0B (RMB 575.2B) | ~flat | ~$8.3B |
| 3 | Roche | SIX: ROG | Switzerland | ~$70B (CHF 61.5B) | +7% CER | ~$370B |
| 4 | Eli Lilly | NYSE: LLY | USA | $65.2B | +45% | ~$1.10–1.15T |
| 5 | Merck & Co. (MSD) | NYSE: MRK | USA | $65.0B | +1% | ~$305B |
| 6 | Pfizer | NYSE: PFE | USA | $62.6B | -2% | ~$150B |
| 7 | AbbVie | NYSE: ABBV | USA | $61.2B | +8.6% | ~$430B |
| 8 | AstraZeneca | NASDAQ: AZN | UK | $58.7B | +9% CER | ~$300B |
| 9 | Novartis | NYSE: NVS | Switzerland | $54.5B | +8% cc | ~$300B |
| 10 | Bristol Myers Squibb | NYSE: BMY | USA | $48.2B | Flat | ~$130B |
| 11 | Sanofi | NASDAQ: SNY | France | ~$47.5B (€43.6B) | +9.9% CER | ~$120B |
| 12 | Novo Nordisk | NYSE: NVO | Denmark | $43.3B | +10% CER | ~$220B |
| 13 | GSK | NYSE: GSK | UK | ~$42.8B (£32.7B) | +7% CER | ~$123B |
| 14 | Amgen | NASDAQ: AMGN | USA | $36.8B | +10% | ~$196B |
| 15 | Boehringer Ingelheim* | Private | Germany | ~$30.3B (€27.8B) | +7.3% | Private (no public market cap) |
| 16 | Gilead Sciences | NASDAQ: GILD | USA | $29.4B | +2% | ~$178B |
| 17 | Takeda Pharmaceutical** | NYSE: TAK | Japan | ~$29.2B | ~flat | ~$55B |
| 18 | Teva Pharmaceutical | NYSE: TEVA | Israel | $17.3B | +4.3% | ~$38B |
| 19 | Regeneron Pharmaceuticals | NASDAQ: REGN | USA | $14.3B | +1% | ~$82B |
| 20 | Astellas Pharma** | NYSE: ALPMY | Japan | ~$13.5B | +varies | ~$29B |
*Sinopharm Group is primarily a pharmaceutical and medical-device distributor/wholesaler rather than an R&D-driven manufacturer (see note below); Boehringer Ingelheim is privately held and discloses no market capitalization. **Takeda and Astellas report on a fiscal year ending March 31; figures reflect the closest comparable 12-month period to calendar 2025. All non-U.S.-dollar figures are approximate conversions using average 2025 exchange rates.
Company-by-Company Breakdown
1. Johnson & Johnson — $94.2 Billion
Johnson & Johnson posted full-year 2025 reported sales growth of 6.0% to $94.2 billion, according to its Q4 and full-year 2025 results. Oncology grew 22% on Innovative Medicine, with Darzalex crossing $14.3 billion and Carvykti nearly doubling to $1.9 billion, while Stelara biosimilar erosion cut Immunology revenue by roughly $4.3 billion. MedTech contributed $33.8 billion. J&J guided to $100–101 billion in 2026 revenue, crossing $100 billion for the first time, and its market cap sat at roughly $600 billion in mid-2026.
2. Sinopharm Group — ~$80.0 Billion (RMB 575.2 Billion)
Sinopharm Group, a core subsidiary of China National Pharmaceutical Group (Sinopharm/CNPGC) listed on the Hong Kong Stock Exchange, reported 2025 group revenue of RMB 575.2 billion, roughly $80 billion, according to its official investor relations disclosures. Sinopharm is China's largest wholesaler and retailer of drugs and medical devices, serving more than 700,000 institutional customers nationwide, with pharmaceutical distribution making up over 70% of revenue and medical device distribution and retail pharmacy (including the Guoda Drugstore chain) contributing the remainder. Despite its enormous top line, Sinopharm's market capitalization is only around $8.3 billion, reflecting the thin margins typical of pharmaceutical distribution and wholesale businesses rather than the high-margin, IP-driven economics of drug manufacturers.
Readers researching this ranking should understand an important structural distinction: Sinopharm Group is a pharmaceutical and medical-device distributor — the Chinese equivalent of McKesson or Cardinal Health in the U.S. — not an R&D-driven drug manufacturer like the other 19 companies on this list. Sinopharm buys, warehouses, and resells medicines and devices made by thousands of manufacturers (domestic and international) through a nationwide logistics network, earning thin distribution margins on enormous transaction volume. That business model explains why Sinopharm's ~$80 billion in revenue would rank it second on this list by top-line sales alone, yet its market capitalization of roughly $8.3 billion is smaller than that of companies with a fraction of its revenue, such as Regeneron ($14.3 billion in revenue, ~$82 billion market cap). Investors and researchers comparing "pharma company size" should treat revenue-based rankings that include distributors like Sinopharm separately from R&D-intensive manufacturer rankings, since profit margins, innovation pipelines, and patent economics are not comparable across the two business models.
3. Roche — ~$70 Billion (CHF 61.5 Billion)
Roche reported group sales of CHF 61.5 billion for 2025, up 7% at constant exchange rates (2% in Swiss francs, reflecting a strong franc). The Pharmaceuticals Division grew 9% CER to CHF 47.7 billion, led by five core growth drivers — Phesgo, Xolair, Ocrevus, Hemlibra and Vabysmo — which together added CHF 21.4 billion. Xolair was the standout at +32% on a new food-allergy indication. Roche has declared an ambition to become a top-3 global obesity company by 2030 and reported competitive Phase 2 obesity data for its candidate CT-388 in early 2026.
4. Eli Lilly and Company — $65.2 Billion
Eli Lilly delivered the industry's standout year, with revenue of $65.2 billion, up 45%, per its Q4 2025 earnings release. Mounjaro nearly doubled to $23.0 billion and Zepbound surged 175% to $13.5 billion, together delivering $36.5 billion — more than the entire annual revenue of Gilead or Amgen. Lilly's oral GLP-1 pill orforglipron (branded Foundayo) won FDA approval in April 2026. The company's market cap crossed $1 trillion in November 2025 and stood at roughly $1.1 trillion by July 2026, making it the world's most valuable healthcare company by a wide margin, with 2026 guidance of $80–83 billion in revenue.
5. Merck & Co. (MSD outside the U.S. and Canada) — $65.0 Billion
Merck's total worldwide sales reached $65.0 billion in 2025, up 1%, according to its full-year 2025 results. Keytruda (pembrolizumab) grew 7% to $31.7 billion and now represents roughly 49% of total revenue, intensifying pressure to diversify ahead of its approximately 2028 patent cliff. Gardasil fell 39% to $5.2 billion on weak China and Japan demand, while newer launches Winrevair ($1.4 billion) and Capvaxive ($759 million) are emerging as diversification pillars. Merck's 2026 guidance of $65.5–67.0 billion came in below Street estimates.
6. Pfizer — $62.6 Billion
Pfizer's 2025 revenue came in at $62.6 billion, down roughly 2%, as COVID-19 products Comirnaty and Paxlovid continued to normalize (combined ~$6.8 billion versus ~$13.1 billion in 2024). Ex-COVID revenue grew 6% operationally, led by Abrysvo, Padcev, and a fast-growing oncology biosimilars business. Pfizer absorbed $4.4 billion in non-cash pipeline impairments in Q4 and has re-entered the obesity category through its 2025 Metsera acquisition. 2026 guidance of $59.5–62.5 billion implies continued softness from loss-of-exclusivity events.
7. AbbVie — $61.2 Billion
AbbVie reported net revenues of $61.2 billion, up 8.6%, successfully completing its post-Humira transition. Skyrizi ($17.56 billion, +50%) and Rinvoq ($8.30 billion, +39%) together generated $25.9 billion, clearing management's 2027 combined-sales target of $27 billion two years early, while Humira continued its decline to $4.54 billion (down from $9.0 billion in 2024). AbbVie's aesthetics segment (Botox Cosmetic, Juvederm) softened, but the company still guided to approximately $67 billion in 2026 revenue.
8. AstraZeneca — $58.7 Billion
AstraZeneca's 2025 revenue reached $58.7 billion, up roughly 9% CER, with oncology contributing $25.6 billion (+14%), or 44% of product revenue, across 16 blockbuster medicines. Imfinzi grew 29% to about $6.1 billion, and AstraZeneca's share of Enhertu (partnered with Daiichi Sankyo) rose 46% to $2.8 billion (roughly $5.2 billion combined globally). In January 2026, AstraZeneca entered an up-to-$18.5 billion partnership with China's CSPC Pharmaceutical for next-generation obesity and diabetes assets, marking its formal entry into the GLP-1 category.
9. Novartis — $54.5 Billion
Novartis, now a pure-play innovative medicines company, reported 2025 revenue of $54.5 billion, up about 8% constant currency, and hit its 40% core operating margin target two years ahead of plan. Heart failure drug Entresto lost U.S. exclusivity in 2025, but breast cancer drug Kisqali grew 57% to $4.8 billion, with Kesimpta (+36%) and Scemblix (+85%) also inflecting strongly. Novartis has flagged 2026 as its highest generic-erosion year in company history.
10. Bristol Myers Squibb — $48.2 Billion
Bristol Myers Squibb's 2025 revenue was roughly flat at $48.2 billion, as its Growth Portfolio overtook Legacy products for the first time, reaching $26.4 billion (+17%) or 55% of total revenue. Eliquis remained resilient at $14.4 billion (+8%), and newer launches Breyanzi (+82%) and Camzyos (+77%) both crossed $1 billion, offsetting a 49% collapse in Revlimid to $3.0 billion as generic competition intensified. BMS guided to $46.0–47.5 billion in 2026 revenue as its Legacy portfolio continues to decline.
11. Sanofi — ~$47.5 Billion (€43.6 Billion)
Sanofi delivered net sales of €43.63 billion, up 9.9%, its strongest growth in years following the divestment of its Opella consumer-health unit. Dupixent, co-developed with Regeneron, generated €15.7 billion (+25.2%), now about 36% of total sales, while newer hemophilia therapy Altuviiio reached blockbuster status at €1.16 billion in its first full year. Sanofi has redeployed Opella proceeds into acquisitions including Blueprint Medicines and, pending close, Dynavax.
12. Novo Nordisk — $43.3 Billion
Novo Nordisk closed a turbulent 2025 with net sales of roughly $43.3 billion (DKK 309 billion), up about 10% at constant exchange rates but only around 4% as reported. Ozempic remained the top product at DKK 127.1 billion, and Obesity Care sales grew 31% CER to DKK 82.3 billion, but a shocking 2026 guidance of -5% to -13% adjusted CER growth triggered an 18% single-day stock decline in February 2026 — the sector's most dramatic reaction of the earnings season. The year also brought a new CEO (Maziar Mike Doustdar), roughly 9,000 job cuts, and the U.S. launch of an oral Wegovy pill in January 2026.
13. GSK — ~$42.8 Billion (£32.7 Billion)
GSK delivered turnover of £32.7 billion, up 7% CER, driven by oncology sales surging 43% (Jemperli nearly doubled) and HIV portfolio growth of 11%, including long-acting therapies Cabenuva and Apretude, up a combined 46%. GSK secured five FDA approvals in 2025 and guided to 3–5% CER turnover growth for 2026.
14. Amgen — $36.8 Billion
Amgen grew revenue 10% to $36.8 billion, with 14 products exceeding $1 billion in annual sales. Repatha surged 36% to $3.0 billion on new cardiovascular outcomes data, and Tezspire grew 52% to $1.5 billion, while Enbrel continued to decline (-33%) from biosimilar erosion. Amgen's most closely watched pipeline asset, obesity candidate MariTide, has six Phase 3 studies underway with results expected in 2026.
15. Boehringer Ingelheim — ~$30.3 Billion (€27.8 Billion)
Boehringer Ingelheim, the largest privately held pharmaceutical company in the world, reported group net sales of €27.8 billion, up 7.3%, spanning its Human Pharma and Animal Health divisions. Key products include cardio-renal-metabolic drug Jardiance and pulmonary fibrosis treatment Ofev, alongside two new 2025 launches: lung cancer drug Hernexeos and pulmonary fibrosis therapy Jascayd. Family- and foundation-controlled since 1885, Boehringer discloses no public market capitalization.
16. Gilead Sciences — $29.4 Billion
Gilead's revenue grew 2% to $29.4 billion, anchored by Biktarvy's HIV dominance ($14.3 billion, +7%, over 52% U.S. market share) and Descovy's 31% growth on PrEP demand. The company faced oncology pipeline setbacks, including a Phase 3 failure for Trodelvy in first-line breast cancer, but continues to expand its HIV franchise toward the 2040s with no near-term patent cliff.
17. Takeda Pharmaceutical — ~$29.2 Billion
Takeda, reporting on a fiscal year ending March 31, guided to approximately JPY 4.3 trillion (roughly $29 billion) in revenue for the period closest to calendar 2025. Entyvio remains the anchor franchise at roughly $4.8 billion for the first nine months, while Vyvanse/Elvanse generic erosion (-46%) has been the dominant headwind. Takeda has flagged three potential multibillion-dollar launches over the next 18 months: oveporexton (narcolepsy), rusfertide (polycythemia vera), and zasocitinib (a TYK2 inhibitor).
18. Teva Pharmaceutical Industries — $17.3 Billion
Teva, the world's largest generic drug manufacturer, reported 2025 net revenues of $17.3 billion, up from $16.5 billion in 2024, according to its SEC filings. Growth was driven by innovative products including Austedo (tardive dyskinesia) and Ajovy (migraine), alongside a resilient generics and biosimilars base. Teva continues executing its "Pivot to Growth" strategy targeting a 30% operating margin, with roughly $700 million in net savings targeted by 2027.
19. Regeneron Pharmaceuticals — $14.3 Billion
Regeneron's company-booked revenue grew only 1% to $14.3 billion, masking the continued strength of Dupixent (global sales of $17.8 billion, +26%, booked primarily by partner Sanofi) because Regeneron's own EYLEA franchise fell 27% to $4.39 billion combined (EYLEA plus EYLEA HD) amid new aflibercept biosimilar competition. Regeneron did not provide specific 2026 revenue guidance.
20. Astellas Pharma — ~$13.5 Billion
Astellas, also reporting on a fiscal year ending March 31, delivered an operational turnaround highlighted by a 52% Q3 EPS beat and a third consecutive upward guidance revision. Prostate cancer drug Xtandi remains the anchor at a forecast ~$6.1 billion for the fiscal year, while five newer strategic brands — led by Padcev (+39%) and Vylay (+831% from a small base) — collectively grew 45%.
Key 2026 Growth Drivers: GLP-1, Oncology & Immunology
- GLP-1 / metabolic drugs: Eli Lilly's Mounjaro and Zepbound ($36.5B combined) and Novo Nordisk's Ozempic and Wegovy remain the industry's largest growth category. New entrants are piling in: AstraZeneca's $18.5B CSPC partnership, Amgen's MariTide, Roche's CT-388, and Pfizer's Metsera-derived pipeline all signal a crowded obesity market by 2027–2028.
- Oncology: Merck's Keytruda ($31.7B), J&J's Darzalex ($14.3B), AstraZeneca's Imfinzi (~$6.1B) and Enhertu (~$5.2B combined with Daiichi Sankyo), and Novartis's Kisqali ($4.8B) anchor immuno-oncology, even as Keytruda's 2028 patent cliff drives sector-wide diversification into antibody-drug conjugates and cell therapies.
- Immunology: AbbVie's Skyrizi and Rinvoq ($25.9B combined) and Sanofi's Dupixent (€15.7B) show how post-patent-cliff franchises can outgrow the blockbusters they replaced.
- Generics and distribution: Teva's steady generics/biosimilars base and Sinopharm's vast Chinese distribution network illustrate that industry scale isn't only built through novel drug discovery.
Frequently Asked Questions
Which pharmaceutical company has the highest revenue in 2026?
Johnson & Johnson, with $94.2 billion in full-year 2025 revenue, up 6.0% year-over-year.
Where does Sinopharm Group rank among global pharmaceutical companies?
By revenue alone, Sinopharm's roughly $80 billion (RMB 575.2 billion) would place it second on this list, but as a distributor rather than an R&D-based drug manufacturer, it is not directly comparable to the other companies ranked here.
Which pharma company has the highest market capitalization?
Eli Lilly, at roughly $1.1 trillion as of July 2026 — the first health-care company ever to cross the trillion-dollar mark.
What is the fastest-growing top pharmaceutical company by revenue?
Eli Lilly, up 45% to $65.2 billion in 2025, driven by Mounjaro and Zepbound.
Which pharmaceutical companies are privately held?
Boehringer Ingelheim, with roughly $30 billion in 2025 net sales, is the largest privately held pharmaceutical company in the world and has no public market capitalization.
Methodology
This ranking is based on each company's audited or company-reported full-year 2025 consolidated revenue as disclosed in official earnings releases and regulatory filings between January and March 2026. Figures reported in non-U.S. currencies (Swiss francs, euros, British pounds, Danish kroner, Chinese renminbi) are converted to approximate U.S. dollars using average 2025 exchange rates and are labeled accordingly. Takeda and Astellas report on a fiscal year ending March 31, so their figures reflect the nearest comparable 12-month period rather than the calendar year. Sinopharm Group's revenue reflects its distribution/wholesale business model and is not directly comparable to R&D-driven pharmaceutical manufacturers (see the dedicated note above). Market capitalization figures are approximate, reflect trading data from June through early July 2026, and fluctuate daily; verify against a live data source before use in investment decisions.
Disclaimer: This article is for general informational purposes only and does not constitute financial, investment, or medical advice. Readers should verify current figures independently and consult a licensed financial advisor before making investment decisions.
Comments